Protagonist Therapeutics, Inc (PTGX) Operating income 2016–2025
Protagonist Therapeutics, Inc (PTGX) annual operating income history from SEC filings — each fiscal year as reported.
-$158.1MFY2025 · since FY2016: -$32.7M → -$158.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$158.1M | -162.5% |
| FY2024 | $252.8M | +370.0% |
| FY2023 | -$93.7M | +28.7% |
| FY2022 | -$131.4M | -4.4% |
| FY2021 | -$125.8M | -95.1% |
| FY2020 | -$64.5M | +19.9% |
| FY2019 | -$80.5M | -90.5% |
| FY2018 | -$42.3M | -11.5% |
| FY2017 | -$37.9M | -16.0% |
| FY2016 | -$32.7M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More PTGX financial trends
PTGX RevenuePTGX Net incomePTGX Net marginPTGX Gross profitPTGX Gross marginPTGX Operating marginPTGX Operating cash flowPTGX Free cash flowPTGX Capital expendituresPTGX Return on equityPTGX Stock buybacksPTGX Dividends paidPTGX Total assetsPTGX Total liabilitiesPTGX Shareholders’ equityPTGX overview →